Jan Pinkas, Chief Scientific Officer of Crescent Biopharma, Inc., filed a Form 4 on September 18, 2026, reporting the automatic sale of 658 ordinary shares on September 16, 2026, to satisfy tax withholding obligations tied to the vesting of restricted stock units.

Key Highlights

  • Shares sold: 658 ordinary shares were disposed of on September 16, 2026, with transaction code "S."
  • Weighted average price: $17.9 per share, with individual transactions ranging from $17.10 to $19.17, inclusive.
  • Purpose: The filing states the shares were "automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units."
  • RSU grant date: The underlying restricted stock units were granted to Pinkas on December 15, 2025.
  • Rule 10b5-1 plan: Sales were effected pursuant to a Rule 10b5-1 instruction adopted by Pinkas on February 26, 2026, "solely with the intent to cover taxes in connection with the vesting of the restricted stock units."
  • Remaining ownership: Following the transaction, Pinkas directly beneficially owns 21,581 ordinary shares.

Jan Pinkas RSU Tax Sale Details at Crescent Biopharma

According to the Form 4 filed with the SEC, Jan Pinkas, Chief Scientific Officer of Crescent Biopharma, Inc. (NASDAQ:CBIO), disposed of 658 ordinary shares on September 16, 2026. The filing indicates the transaction was not a discretionary open-market sale but was instead an automatic disposition to cover tax withholding obligations arising from the settlement of restricted stock units originally granted on December 15, 2025.

The filing reports a weighted average sale price of $17.9 per share. The shares were sold across multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The filing notes that Pinkas "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price." The transaction was executed under a Rule 10b5-1 trading instruction adopted by Pinkas on February 26, 2026. The form was signed by Barbara Bispham Hale as attorney-in-fact for Jan Pinkas and dated September 18, 2026.

Following the reported transaction, the filing discloses that Pinkas directly holds 21,581 ordinary shares of Crescent Biopharma. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing discloses a single disposal of 658 ordinary shares by Crescent Biopharma's Chief Scientific Officer at a weighted average price of $17.9, executed automatically under a pre-established Rule 10b5-1 plan to cover RSU-related tax withholding, leaving him with 21,581 shares directly held.